These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 7834645)
1. Genetic polymorphism and cancer susceptibility: fourteenth Sapporo Cancer Seminar. Gonzalez FJ Cancer Res; 1995 Feb; 55(3):710-5. PubMed ID: 7834645 [No Abstract] [Full Text] [Related]
2. Metabolic polymorphisms and carcinogen-DNA adduct formation in human populations. Kaderlik KR; Kadlubar FF Pharmacogenetics; 1995; 5 Spec No():S108-17. PubMed ID: 7581479 [TBL] [Abstract][Full Text] [Related]
3. Assessment of cancer susceptibility in humans by use of genetic polymorphisms in carcinogen metabolism. Ikawa S; Uematsu F; Watanabe K; Kimpara T; Osada M; Hossain A; Sagami I; Kikuchi H; Watanabe M Pharmacogenetics; 1995; 5 Spec No():S154-60. PubMed ID: 7581487 [TBL] [Abstract][Full Text] [Related]
4. Cytochrome P-450 and acetyltransferase expression as biomarkers of carcinogen-DNA adduct levels and human cancer susceptibility. Badawi AF; Stern SJ; Lang NP; Kadlubar FF Prog Clin Biol Res; 1996; 395():109-40. PubMed ID: 8895986 [TBL] [Abstract][Full Text] [Related]
5. The role of carcinogen-metabolizing enzyme polymorphisms in cancer susceptibility. Gonzalez FJ Reprod Toxicol; 1997; 11(2-3):397-412. PubMed ID: 9100315 [No Abstract] [Full Text] [Related]
6. Interactions of cancer susceptibility genes and environmental carcinogens. American Association for Cancer Research (AACR)-International Agency for Research on Cancer (IARC) Joint Conference. Li FP; Montesano R Cancer Res; 1994 Aug; 54(15):4243-7. PubMed ID: 8033156 [No Abstract] [Full Text] [Related]
7. Individuality in cytochrome P450 expression and its association with the nephrotoxic and carcinogenic effects of chemicals. Wolf CR IARC Sci Publ; 1991; (115):281-7. PubMed ID: 1820342 [TBL] [Abstract][Full Text] [Related]
8. Proceedings of the 14th Sapporo Cancer Seminar on genetic polymorphism and cancer susceptibility. 6-9 July 1994. Pharmacogenetics; 1995; 5 Spec No():i, S59-176. PubMed ID: 7581477 [No Abstract] [Full Text] [Related]
9. DNA adducts of 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in colon, bladder, and kidney of congenic mice differing in Ah responsiveness and N-acetyltransferase genotype. Nerurkar PV; Schut HA; Anderson LM; Riggs CW; Snyderwine EG; Thorgeirsson SS; Weber WW; Rice JM; Levy GN Cancer Res; 1995 Jul; 55(14):3043-9. PubMed ID: 7606725 [TBL] [Abstract][Full Text] [Related]
10. DNA adducts of nitrosamines. Shuker DE; Bartsch H IARC Sci Publ; 1994; (125):73-89. PubMed ID: 7806342 [No Abstract] [Full Text] [Related]
11. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Bartsch H; Nair U; Risch A; Rojas M; Wikman H; Alexandrov K Cancer Epidemiol Biomarkers Prev; 2000 Jan; 9(1):3-28. PubMed ID: 10667460 [TBL] [Abstract][Full Text] [Related]
12. Sulfonation in chemical carcinogenesis--history and present status. Miller JA Chem Biol Interact; 1994 Jun; 92(1-3):329-41. PubMed ID: 8033266 [TBL] [Abstract][Full Text] [Related]
14. [Genes and enzymes involved in the metabolism of carcinogens]. Trédaniel J; Zalcman G; Douriez E Bull Cancer; 1995; 82 Suppl 2():77s-84s. PubMed ID: 7626862 [TBL] [Abstract][Full Text] [Related]
15. Human drug-metabolizing enzyme polymorphisms: effects on risk of toxicity and cancer. Nebert DW; McKinnon RA; Puga A DNA Cell Biol; 1996 Apr; 15(4):273-80. PubMed ID: 8639263 [TBL] [Abstract][Full Text] [Related]
16. Selection of candidate genes for population studies. Caporaso N IARC Sci Publ; 1999; (148):23-36. PubMed ID: 10493246 [TBL] [Abstract][Full Text] [Related]
17. Arsenic methylation, oxidative stress and cancer--is there a link? Hughes MF J Natl Cancer Inst; 2009 Dec; 101(24):1660-1. PubMed ID: 19933940 [No Abstract] [Full Text] [Related]
18. DNA adducts of aflatoxins, sterigmatocystin and other mycotoxins. McConnell IR; Garner RC IARC Sci Publ; 1994; (125):49-55. PubMed ID: 7806340 [No Abstract] [Full Text] [Related]
19. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Bozina N; Bradamante V; Lovrić M Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216 [TBL] [Abstract][Full Text] [Related]
20. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Smith CA; Moss JE; Gough AC; Spurr NK; Wolf CR Environ Health Perspect; 1992 Nov; 98():107-12. PubMed ID: 1486838 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]